REGENXBIO Inc.
REGENXBIO Inc. (RGNX): 19 pipeline candidates · 2 upcoming catalysts · ~6 mo cash runway · 8 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
6.1 months
D/E 15.22 · 2% dilution
Lead: Phase 3
19 candidates
2 upcoming, next in ~1807d
0 buys · 2 sells (180d)
A transparent, data-derived signal for REGENXBIO Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$441.5M
Cash
$17.3M
Quarterly Burn
$76.2M
Runway
6.1 mo
Revenue
$6.4M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (19 candidates)
| Drug | Phase |
|---|---|
| ABBV-RGX-314 | Phase 3 |
| Amivantamab | Phase 3 |
| Biweekly FOLFIRI | Phase 2 |
| Biweekly Modified FOLFOX6 | Phase 2 |
| Cetuximab | Phase 3 |
| FOLFIRI | Phase 1 |
| FOLFIRI regimen | Phase 2 |
| FOLFOX | Phase 1 |
| Inavolisib | Phase 2 |
| JNJ-89402638 | Phase 1 |
Showing 10 of 19 candidates. Sign up for full pipeline.
Upcoming Catalysts (2)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
175
Total value held
$305.9M
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 5,782,808 | $48.5M |
| vanguard capital management llc | 4,014,292 | $33.6M |
| state street corp | 2,731,485 | $22.9M |
| eversource wealth advisors, llc | 81,463 | $20.2M |
| morgan stanley | 2,066,157 | $17.3M |
| goldman sachs group inc | 1,839,463 | $15.4M |
| geode capital management, llc | 1,137,498 | $9.5M |
| aqr capital management llc | 1,051,712 | $8.8M |
| vanguard portfolio management llc | 1,018,901 | $8.5M |
| dimensional fund advisors lp | 1,010,381 | $8.5M |
Showing top 10 of 175 institutional holders of REGENXBIO Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in REGENXBIO Inc.'s pipeline?
REGENXBIO Inc. (RGNX) has 19 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is REGENXBIO Inc.'s lead drug candidate?
REGENXBIO Inc.'s most advanced tracked candidate is ABBV-RGX-314 (Phase 3) for Wet age-related macular degeneration (wet AMD) and diabetic retinopathy (DR).
What is REGENXBIO Inc.'s next catalyst?
REGENXBIO Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Open-Label Study to Evaluate the Efficacy, Safety, and Pharmacodynamics of RGX 121 in Ped" — expected May 30, 2031.
What is REGENXBIO Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, REGENXBIO Inc. has approximately 6.1 months of cash runway.
What is REGENXBIO Inc.'s market capitalization?
REGENXBIO Inc.'s market capitalization is approximately $441.5M.
Get the full picture on REGENXBIO Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.